The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a condition for Aurobindo Pharma to finalize its acquisition of Lannett Company Inc., ensuring no anti-competitive issues arise from the deal.
Source link
Trending
- Lopsided solution: On syrup-based medicines, doctor’s prescription
- Glenmark Launches Generic Methylene Blue Injection in US, Targets USD 19 Million Market
- Valve is so behind on Steam Controller orders that some won’t ship till 2027
- OpenAI is bringing on some big guns in the lead-up to its IPO
- EPF interest rate retained at 8.25% for FY26
- Govt targets 69% jump in FY27 rural road construction
- The Iran oil shock taught traders these key lessons about demand and China
- Despite West Asia crisis, net direct tax mopup grows 15% to Rs 5.2 lakh crore
